Move over, Novartis: Kite and Gilead break into CAR-T market with early axi-cel nod

When non-Hodgkin lymphoma patient Becky Revoir learned last year that her cancer was pushed into remission by Kite Pharma’s experimental CAR-T treatment, she had one big wish. “My hope is that no patient ever has to hear that their chemo didn’t work and they have no other treatment options,” said Revoir, 51, in an interview with FiercePharma.